OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TOPV56

TOPVISION Eye Specialist Bhd

Healthcare Facilities & ServicesVerified

TOPVISION Eye Specialist Bhd has a debt-to-equity ratio of 0.65 and a current ratio of 4.1, indicating a relatively strong liquidity position despite a negative net cash position after subtracting total debt. The company’s free cash flow is negative at -4.54 million MYR, driven by capital expenditures of -6.49 million MYR, which suggests ongoing investment in infrastructure or equipment. Profitability metrics show a return on equity of 4.45% and a return on assets of 2.54%, both below the typical thresholds for high-margin healthcare services. This suggests the company is generating modest returns relative to its equity and asset base. Operating income of 5.65 million MYR and a gross profit of 22.87 million MYR indicate a stable but not exceptional performance in cost management and pricing. The company operates through multiple branches across Malaysia, including locations in Setia Alam, Banting, and Johor Bahru, with no disclosed segmental revenue breakdown. This lack of segmental data limits visibility into geographic or service-line concentration risks. Revenue for the latest period is 45.81 million MYR, with no disclosed growth rate or outlook. The absence of forward-looking guidance and limited historical data makes it difficult to assess the company’s growth trajectory. Risk factors include a medium liquidity risk due to negative net cash and a current reliance on operating cash flow of 6.98 million MYR to fund operations. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. Recent events include no disclosed filings or transcripts, and the company’s financial disclosures are limited to standard balance sheet and income statement items. This suggests a lack of transparency in strategic or operational developments.

30-day price · TOPV+0.01 (+6.5%)
Low$0.15High$0.17Close$0.17As of17 May, 00:00 UTC
Profile
CompanyTOPVISION Eye Specialist Bhd
TickerTOPV.KL
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. TOPVISION Eye Specialist Bhd provides ophthalmology services and related medical consultancy in Malaysia, operating through multiple branches and subsidiaries focused on treating eye conditions such as cataract, diabetic retinopathy, and glaucoma.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

TOPVISION Eye Specialist Bhd has a debt-to-equity ratio of 0.65 and a current ratio of 4.1, indicating a relatively strong liquidity position despite a negative net cash position after subtracting total debt. The company’s free cash flow is negative at -4.54 million MYR, driven by capital expenditures of -6.49 million MYR, which suggests ongoing investment in infrastructure or equipment. Profitability metrics show a return on equity of 4.45% and a return on assets of 2.54%, both below the typical thresholds for high-margin healthcare services. This suggests the company is generating modest returns relative to its equity and asset base. Operating income of 5.65 million MYR and a gross profit of 22.87 million MYR indicate a stable but not exceptional performance in cost management and pricing. The company operates through multiple branches across Malaysia, including locations in Setia Alam, Banting, and Johor Bahru, with no disclosed segmental revenue breakdown. This lack of segmental data limits visibility into geographic or service-line concentration risks. Revenue for the latest period is 45.81 million MYR, with no disclosed growth rate or outlook. The absence of forward-looking guidance and limited historical data makes it difficult to assess the company’s growth trajectory. Risk factors include a medium liquidity risk due to negative net cash and a current reliance on operating cash flow of 6.98 million MYR to fund operations. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. Recent events include no disclosed filings or transcripts, and the company’s financial disclosures are limited to standard balance sheet and income statement items. This suggests a lack of transparency in strategic or operational developments.
Key takeaways
  • The company maintains a strong current ratio of 4.1 but faces liquidity challenges due to negative net cash after debt.
  • Return on equity and return on assets are below typical thresholds for healthcare service providers, indicating modest profitability.
  • The company operates in multiple locations across Malaysia but lacks segmental revenue disclosure, limiting visibility into geographic concentration.
  • Free cash flow is negative, driven by capital expenditures, suggesting ongoing investment in infrastructure.
  • Dilution risk is low, and no near-term share issuance pressure is evident.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyMYR
Revenue$45.8M
Gross profit$22.9M
Operating income$5.7M
Net income$1.9M
R&D
SG&A
D&A
SBC
Operating cash flow$7.0M
CapEx-$6.5M
Free cash flow-$4.5M
Total assets$74.9M
Total liabilities$32.1M
Total equity$42.8M
Cash & equivalents
Long-term debt$27.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$42.8M
Net cash-$27.6M
Current ratio4.1
Debt/Equity0.7
ROA2.5%
ROE4.5%
Cash conversion3.7%
CapEx/Revenue-14.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricTOPVActivity
Op margin12.3%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin4.2%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin49.9%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-14.2%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity65.0%71.3% medp25 19.0% · p75 91.7%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 23:55 UTC#2ba0849f
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 23:57 UTCJob: f2d00613